Margetuximab
Generic name: Margetuximab
Brand names: Margenza
Dosage form: intravenous solution (25 mg/mL)
Drug class:
HER2 inhibitors
Usage of Margetuximab
Margetuximab is used in combination with other cancer drugs to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic).
Margetuximab is for use in people who have received at least two prior chemotherapy treatments for HER2-positive breast cancer.
Your doctor will test to make sure your cancer has an abnormal "HER2/neu" gene (a specific genetic marker).
Margetuximab may also be used for purposes not listed in this medication guide.
Margetuximab side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver if you feel dizzy, tired, nauseated, light-headed, itchy, sweaty, feverish, chilled, or have a headache, rash, joint pain, cough, fast heartbeats, trouble breathing, or swelling in your face.
Margetuximab may cause serious side effects. Call your doctor at once if you have:
Common side effects of margetuximab may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Margetuximab
Tell your doctor if you have ever had heart problems.
You may need to have a negative pregnancy test before starting this treatment.
Margetuximab may harm an unborn baby. Use effective birth control to prevent pregnancy, and tell your doctor if you become pregnant. Keep using birth control for at least 4 months after your last dose.
It may not be safe to breastfeed while using margetuximab, and for at least 4 months after your last dose. Ask your doctor about any risk.
Relate drugs
- Ado-trastuzumab emtansine
- Enhertu
- Fam-trastuzumab deruxtecan
- Fam-trastuzumab deruxtecan-nxki
- Herceptin
- Herceptin Hylecta
- Herzuma
- Herzuma (Trastuzumab Intravenous)
- Herzuma (Trastuzumab-pkrb Intravenous)
- Hyaluronidase and trastuzumab
- Hyaluronidase, pertuzumab, and trastuzumab
- Kadcyla
- Margenza
- Margetuximab
- Margetuximab-cmkb
- Ogivri
- Ogivri (Trastuzumab Intravenous)
- Ogivri (Trastuzumab-dkst Intravenous)
- Ontruzant
- Ontruzant (Trastuzumab Intravenous)
- Ontruzant (Trastuzumab-dttb Intravenous)
- Perjeta
- Pertuzumab
- Pertuzumab, trastuzumab, and hyaluronidase-zzxf
- Phesgo
- Trastuzumab
- Trastuzumab and hyaluronidase-oysk
- Trastuzumab-anns
- Trastuzumab-dkst
- Trastuzumab-dttb
- Trastuzumab-pkrb
- Trazimera
- Tucatinib
- Tukysa
How to use Margetuximab
Usual Adult Dose for Breast Cancer:
15 mg/kg IV every 3 weeks Comment:-Infuse initial dose over 120 minutes and subsequent doses over 30 minutes. -This drug may be administered immediately after the completion of chemotherapy.-Continue treatment until disease progression or unacceptable toxicity.-All therapeutic proteins, including this drug, have the potential to produce an immune response.Use: In combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease
Warnings
Margetuximab may cause heart problems. Call your doctor at once if you have symptoms such as: fast or pounding heartbeats, cough, shortness of breath, swelling, or rapid weight gain.
What other drugs will affect Margetuximab
margetuximab can have long-lasting effects on your body. For at least 4 months after your last dose of margetuximab, you should not be treated with certain other cancer drugs. Tell each of your doctors about your treatment with margetuximab.
Other drugs may affect margetuximab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions